根据郑州大学附属肿瘤医院的一项临床研究，研究者对14例经过TKI规范治疗且自愿停药的儿童进行了详尽的临床分析。这些患儿在接受治疗后达到了稳定的深层分子学反应（DMR）≥2年，最终结果显示，有部分患儿成功实现了停药后的无治疗缓解（TFR）。

为解决慢性髓性白血病（CML）孕期治疗难题，研究人员开展相关研究，发现 asciminib 暴露未致畸且停药后 MMR 可恢复。 # 慢性髓性白血病患者孕期服用 asciminib 成功诞下双胞胎：罕见案例带来的新启示 在白血病的大家族里，慢性髓性白血病（Chronic Myeloid Leukemia ...

总之，普纳替尼的临床应用是肿瘤治疗史上“向死而生”的典范。其以突破性疗效拯救无数濒危患者的同时，也迫使医学界重新审视“风险-获益”的伦理边界。未来，随着分子分型的精细化与毒性管理手段的革新，普纳替尼或将褪去“最后选择”的悲情色彩，进化为兼顾安全与疗效的治愈利器。在这条充满挑战的征途上，科学与人文的交织，终将照亮白血病治疗的终极愿景。 返回搜狐，查看更多 ...

The MMR rate was 66% at 6 months and 85% at 12 months ... early-stage, chronic-phase Ph+ CML patients” comment the researchers. The investigators also noted that the magnitude and rapidity ...

MMR was 47% after 12 months and 73% after 24 months ... in patients with pretreated late phase CML-CP within a randomized Phase III trial. The first interim analysis suggests that HD induction ...

The 405-patient phase 3 study showed that 68% of those treated with Scemblix had a major molecular response (MMR) after 48 weeks ... of choice” for CML. The trial remains ongoing, with the ...

CML Unlocks AI’s Full Potential with Enhanced Pattern Recognition, Prediction, and Real-Time Decision-Making for Defense, Autonomous Systems, and Next-Gen Computing BOULDER, Colo., March 20 ...

In ASC4FIRST, 68% of patients treated with Scemblix had a major molecular response (MMR) after 48 weeks ... dramatic impact that TKIs have had in CML – including a tripling in the five-year ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate ... of 6-month major molecular response (MMR) TERN-601: Oral, small-molecule glucagon ...